ALK and non-small cell lung carcinoma: Because the incidence of ALK rearrangement is low in unselected NSCLC patients (2–5%) [6]–[14], it is necessary to elucidate clinicopathological and molecular characteristics of ALK-positive lung cancer to improve screening efficiency.